Table 4.
Characteristics of patients treated with immunotherapy.
| Type of cancer | Metastasis | IHC | MSI-PCR | Type and period of immunotherapy | Line of treatment | Response | Genetic syndrome |
|---|---|---|---|---|---|---|---|
| CRC | Liver peritoneum | Isolated loss of MSH6 | MSI-H | PEMBROLIZUMAB (12/2015 - 12/2017) | 6th | Complete response | Not investigated |
| Cholangiocarcinoma | Peritoneum | MLH1/PMS2 loss | MSS | PEMBROLIZUMAB (03/2016 - 11/2016) | 2nd | Partial response for 7 months, then progression and death | Lynch (MLH1) |
| Gastric carcinoma | Lymph nodes, Liver, adrenal gland | Isolated loss of MSH6 | MSS | NIVOLUMAB + anti-LAG3 (11/2016 - 04/2018) | 2nd | Complete response | Not identified |
| CRC | Liver peritoneum | MLH1/PMS2 loss | MSS | PEMBROLIZUMAB (12/2017 - 10/2018) | 2nd | Partial response for 10 months, then progression | Not investigated |
| Peritoneal mucinous carcinoma | Peritoneum Lung | Isolated loss of MSH2 | MSI-H | PEMBROLIZUMAB (12/2017 - still treated) | 1st | Stable disease | Lynch (MSH2) |
CRC colorectal carcinoma, IHC immunohistochemistry, MSI-H MSI High.